Fri, January 28, 2022

Mani Foroohar Maintained (ARWR) at Hold with Increased Target to $46 on, Jan 28th, 2022

Mani Foroohar of SVB Leerink, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold with Increased Target from $45 to $46 on, Jan 28th, 2022.

Mani has made no other calls on ARWR in the last 4 months.



There is 1 other peer that has a rating on ARWR. Out of the 1 peers that are also analyzing ARWR, 0 agree with Mani's Rating of Hold.



This is the rating of the analyst that currently disagrees with Mani


  • Madhu Kumar of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Wednesday, January 19th, 2022